Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers

Ohtani,Tomoko; Yamada,Yoichi; Furuhashi,Akifumi; Ohmura,Yukinobu; Nakamura,Sayaka; Kato,Hidefumi; Yoshikawa,Kazuhiro; Kazaoka,Yoshiaki

doi:10.3892/ijo.2014.2599

Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers

Authors:
- Tomoko Ohtani
- Yoichi Yamada
- Akifumi Furuhashi
- Yukinobu Ohmura
- Sayaka Nakamura
- Hidefumi Kato
- Kazuhiro Yoshikawa
- Yoshiaki Kazaoka
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan, Department of Transfusion Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan, Cell Therapy Center of Biochemistry, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan
Published online on: August 14, 2014 https://doi.org/10.3892/ijo.2014.2599
Pages: 2051-2057

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Conventional cancer treatments are surgery, radiotherapy, and chemotherapy, but treatment efficiency is insufficient and cancer recurrence is common. Immunotherapy has been added as an important cancer treatment component, but no reports on its efficacy in oral and maxillofacial cancers exist. We evaluated the clinical efficacy of adoptive immunotherapy using ex vivo-activated cytotoxic T lymphocytes (CTL) in the treatment of 7 patients with advanced oral and maxillofacial cancers with stage IV disease at diagnosis. The mean follow-up period was 26.2 months. Phenotype of the lymphocyte assay revealed that the percentage of CD4+ T cells decreased and that of CD8+ T cells increased among infused lymphocytes compared to that in unstimulated peripheral blood mononuclear cells (PBMCs), and infused lymphocytes produced a significantly higher level of IFN-γ than PBMCs or tumor cells alone. In a representative patient who refused surgery tumor regression was confirmed after CTL infusion. Computed tomography clearly indicated a significant reduction in tumor size followed by the complete disappearance of the tumor. Histological examination showed that the cancers in patients receiving CTL therapy were heavily infiltrated with lymphocytes. The other 2 patients who received CTL therapy as adjuvant therapy showed neither recurrent disease nor new disease lesions. The 1-year survival rates showing response and those with progressive disease were 100 and 25%, respectively. Moreover, no significant adverse reactions were reported during the study period. CTL therapy remains in the early stages of treatment options, but it has potential as a valuable treatment and improvement of quality of life for patients with otherwise incurable cancers.

View Figures

View References

1	World Health Organization. The World Health Report 2004: Changing history. WHO; Geneva: 2004
2	DeVita VT Jr and Rosenberg SA: Two hundred years of cancer research. N Engl J Med. 366:2207–2214. 2012.PubMed/NCBI
3	Colevas AD: Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 10:2644–2652. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 313:1485–1492. 1985. View Article : Google Scholar
5	Ettinghausen SE, Puri RK and Rosenberg SA: Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst. 80:177–188. 1988. View Article : Google Scholar : PubMed/NCBI
6	Soda H, Koda K, Yasutomi J, et al: Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes. J Surg Oncol. 72:211–217. 1999. View Article : Google Scholar : PubMed/NCBI
7	Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP and Papamichail M: Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer. 74:1275–1282. 1994. View Article : Google Scholar : PubMed/NCBI
8	Knuth A, Wolfel T and Meyer zum Buschenfelde KH: T cell responses to human malignant tumors. Cancer Surv. 13:39–52. 1992.PubMed/NCBI
9	Desombere I, Meuleman P, Rigole H, et al: The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level. J Immunol Methods. 286:167–185. 2004. View Article : Google Scholar : PubMed/NCBI
10	Straathof KC, Bollard CM, Popat U, et al: Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 105:1898–1904. 2005. View Article : Google Scholar : PubMed/NCBI
11	Marijt E, Wafelman A, van der Hoorn M, et al: Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica. 92:72–80. 2007. View Article : Google Scholar
12	Toh U, Yamana H, Sueyoshi S, et al: Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res. 6:4663–4673. 2000.PubMed/NCBI
13	Yee C, Thompson JA, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8⁺ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 99:16168–16173. 2002.
14	da Silva SD, Hier M, Mlynarek A, Kowalski LP and Alaoui-Jamali MA: Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol. 3:1492012.PubMed/NCBI
15	Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 91:3515–3519. 1994. View Article : Google Scholar : PubMed/NCBI
16	Saitoh S, Kurisaka M, Mori K, Maeda N and Fujimoto S: Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation. Jpn J Cancer Res. 88:289–295. 1997. View Article : Google Scholar : PubMed/NCBI
17	Restifo NP, Dudley ME and Rosenberg SA: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 22:269–281. 2012. View Article : Google Scholar : PubMed/NCBI
18	Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986. View Article : Google Scholar : PubMed/NCBI
19	Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 17:4550–4557. 2011. View Article : Google Scholar
20	Khammari A, Nguyen JM, Pandolfino MC, et al: Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother. 56:1853–1860. 2007. View Article : Google Scholar : PubMed/NCBI
21	Ratto GB, Zino P, Mirabelli S, et al: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer. 78:244–251. 1996. View Article : Google Scholar
22	Agra IM, Filho JG, Martins EP and Kowalski LP: Second salvage surgery for re-recurrent oral cavity and oropharynx carcinoma. Head Neck. 32:997–1002. 2010. View Article : Google Scholar : PubMed/NCBI